Post Approval Safety Study (Pass): Post-marketing Observational Cohort Study Of Patients With Inflammatory Bowel Disease (Ibd) Treated With Inflectra (Infliximab) In Usual Clinical Practice (Connect-ibd)

Trial Profile

Post Approval Safety Study (Pass): Post-marketing Observational Cohort Study Of Patients With Inflammatory Bowel Disease (Ibd) Treated With Inflectra (Infliximab) In Usual Clinical Practice (Connect-ibd)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 09 Mar 2018

At a glance

  • Drugs Infliximab (Primary)
  • Indications Crohn's disease; Ulcerative colitis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CONNECT-IBD
  • Sponsors Hospira; Pfizer
  • Most Recent Events

    • 05 Mar 2018 Status changed from recruiting to active, no longer recruiting.
    • 08 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top